Wellstein A, Belz G G, Palm D
Zentrum Pharmakologie, Klinikum der J. W. Goethe-Universität, Frankfurt, W. Germany.
J Pharmacol Exp Ther. 1988 Jul;246(1):328-37.
In the present study we investigated whether the beta adrenoceptor subtype binding activity in plasma samples can predict selective and nonselective beta blockade in humans. From the right shifts of isoprenaline dose-response curves 0 to 84 hr after administration of propranolol and the beta-1 selective bisoprolol, in vivo beta blockade was assessed. In an in vitro radioreceptor assay with membrane preparations of beta-1 or beta-2 adrenoceptors, plasma samples were assayed for subtype selective blocking activity. After propranolol administration, in vitro beta-1 and beta-2 adrenoceptor occupancy declined from initially 97% to less than 10% within 48 hr. An isoprenaline dose ratio (DR)-1 of 1 coincided with a 50% occupancy of the beta-1 or the beta-2 subtype in vitro. In Schild-plots using plasma concentrations (radioreceptor assay) and the isoprenaline DR-1 for heart rate, diastolic blood pressure and inotropy (QS2C), slopes of unity were observed. After bisoprolol administration, in vitro beta-1 occupancy shifted from initially 95% to less than 10% within 72 hr. For the beta-2 subtype, an occupancy of greater than 10% was detectable only within the first 12 hr. An isoprenaline DR-1 of 1 coincided with a 50% occupancy of beta-1 adrenoceptors. The bisoprolol Schild-plots yielded a slope of unity for inotropy, but less than unity for the heart rate and diastolic blood pressure. From an extended analysis of subtype selective antagonism in Schild-plots, the fractions of the beta-2 adrenoceptor subtype participating in the isoprenaline response were calculated: heart rate 0.45 +/- 0.12 and diastolic blood pressure 0.23 +/- 0.13. It is concluded that in vitro receptor occupancy can predict beta blockade in humans for propranolol. Beta adrenoceptor subtype-mediated effects in humans can be evaluated with a selective antagonist and a refined analysis of Schild-plot data.
在本研究中,我们调查了血浆样本中的β肾上腺素能受体亚型结合活性是否能够预测人体中的选择性和非选择性β受体阻滞剂作用。通过在给予普萘洛尔和β1选择性比索洛尔后0至84小时内异丙肾上腺素剂量反应曲线的右移,评估体内β受体阻滞剂作用。在一项使用β1或β2肾上腺素能受体膜制剂的体外放射受体分析中,检测血浆样本的亚型选择性阻断活性。给予普萘洛尔后,体外β1和β2肾上腺素能受体占有率在48小时内从最初的97%下降至低于10%。体外异丙肾上腺素剂量比(DR)-1为1时,与β1或β2亚型50%的占有率一致。在使用血浆浓度(放射受体分析)和异丙肾上腺素DR-1对心率、舒张压和心肌收缩力(QS2C)进行的Schild图分析中,观察到斜率为1。给予比索洛尔后,体外β1占有率在72小时内从最初的95%下降至低于10%。对于β2亚型,仅在最初12小时内可检测到大于10%的占有率。异丙肾上腺素DR-1为1时,与β1肾上腺素能受体50%的占有率一致。比索洛尔的Schild图分析得出心肌收缩力的斜率为1,但心率和舒张压的斜率小于1。通过对Schild图中亚型选择性拮抗作用的扩展分析,计算出参与异丙肾上腺素反应的β2肾上腺素能受体亚型的比例:心率为0.45±0.12,舒张压为0.23±0.13。结论是,体外受体占有率可以预测普萘洛尔在人体中的β受体阻滞剂作用。使用选择性拮抗剂和对Schild图数据的精细分析,可以评估人体中β肾上腺素能受体亚型介导的效应。